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Abstract
Multiple targeted therapeutics for Huntington's disease are now in clinical trials, in-
cluding intrathecally delivered compounds. Previous research suggests that CSF dy-
namics may be altered in Huntington's disease, which could be of paramount 
relevance to intrathecal drug delivery to the brain. To test this hypothesis, we con-
ducted a prospective cross- sectional study comparing people with early stage 
Huntington's disease with age- and gender- matched healthy controls. CSF peak ve-
locity, mean velocity and mean flow at the level of the cerebral aqueduct, and sub- 
arachnoid space in the upper and lower spine, were quantified using phase contrast 
MRI. We calculated Spearman's rank correlations, and tested inter- group differences 
with Wilcoxon rank- sum test. Ten people with early Huntington's disease, and 10 
controls were included. None of the quantified measures was associated with poten-
tial modifiers of CSF dynamics (demographics, osmolality, and brain volumes), or 
by known modifiers of Huntington's disease (age and HTT CAG  repeat length); and 
no significant differences were found between the two studied groups. While exter-
nal validation is required, the attained results are sufficient to conclude tentatively 
that a clinically relevant alteration of CSF dynamics – that is, one that would justify 
dose- adjustments of intrathecal drugs – is unlikely to exist in Huntington's disease.
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1 |  INTRODUCTION
Huntington's disease is a fatal, incurable inherited neu-
rodegenerative disorder. Caused by a CAG (cytosine- 
adenine- guanine)- triplet repeat expansion in the HTT gene, 
symptoms usually begin in mid- adulthood, and include 
motor, cognitive, and psychiatric disturbances (Bates et al., 
2015; Rodrigues et al., 2017). Among the most promis-
ing therapeutic strategies are antisense oligonucleotides 
(ASOs), administered intrathecally, intended to diminish 
production of the causative mutant huntingtin protein (Wild 
& Tabrizi, 2017).
In the subarachnoid space throughout the neuraxis, cere-
brospinal fluid (CSF) has a pulsatile to and fro movement, 
with local exchanges happening among CSF, interstitial fluid, 
and blood (Brinker, Stopa, Morrison, & Klinge, 2014). This 
oscillation can also be used for drug delivery from the spinal 
intrathecal space to the brain. In Huntington's disease, three 
experimental therapeutic ASOs are currently being tested 
by this route (reviewed in Rodrigues & Wild, 2017; Wild & 
Tabrizi, 2017; Rodrigues & Wild, 2018). It is important to 
understand whether the delivery of intrathecally administered 
substances to the brain may be altered by disease- related 
variations in CSF flow.
There is evidence that CSF flow dynamics could be al-
tered in Huntington's disease. Large cohort studies have 
identified clear patterns of brain atrophy (Paulsen et al., 
2006; Tabrizi et al., 2013) that might alter CSF dynamics 
by changing resistance to CSF flow. Furthermore ependy-
mal cilia are morphologically abnormal in post- mortem 
Huntington's disease patient brain, and reduced CSF flow 
has been shown in ex vivo organotypic brain slices from 
transgenic Huntington's disease mice (Keryer et al., 2011). 
A case report of atypical performance of spinal anaesthe-
sia in an Huntington's disease patient (Draisci et al., 2012) 
raises the suspicion that these Huntington's disease- related 
changes may together produce clinically relevant alterations 
of CSF dynamics.
This could have important consequences for the distribu-
tion of central nervous system (CNS)- delivered drugs, mer-
iting consideration in the planning of clinical trial regimens. 
However, despite this, the dynamics of CSF flow through the 
brain and spine have never been studied directly in humans 
with Huntington's disease.
Phase Contrast Magnetic Resonance Imaging (PCMRI) 
generates signal contrast between flowing and stationary 
nuclei, such that the signal phase in each image pixel is di-
rectly proportional to the magnitude of the local flow veloc-
ity, enabling the characterisation of fluid dynamics in vivo 
(Nitz et al., 1992; O'Donnell, 1985). Using PCMRI gated to 
the cardiac cycle, it is possible to noninvasively measure the 
dynamics of moving biofluids, specifically CSF, and hence 
quantify velocity and flow rates.
2 |  MATERIALS AND METHODS
This study was designed in line with The Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement (von Elm et al., 2007). Statistical re-
porting is in accordance with the Statistical Analyses and 
Methods in the Published Literature guidelines (SAMPL; 
Lang & Altman, 2013).
2.1 | Study design and participants
We conducted a prospective cross- sectional pilot study 
named “Phase1- HD” involving participants enrolled simul-
taneously in the Enroll- HD study (CHDI Foundation, 2012) 
an international multicentre, prospective registry, and in 
the HD- CSF study (Byrne, Rodrigues, Johnson, De Vita, 
et al., 2018; Byrne, Rodrigues, Johnson, Wijeratne, et al., 
2018), a single- centre prospective cohort based at the UCL 
Huntington's Disease Centre, London, UK.
The main goal of Phase1- HD was to establish the meth-
ods for and feasibility of applying PCMRI to people with 
Huntington's disease and to generate exploratory data to in-
form current practice and design future definitive studies.
Ten healthy volunteers were recruited before study start 
for scanner optimization, and their data were not used in any 
of the analyses. All gave written informed consent.
Ten people with early manifest Huntington's disease and 
10 healthy controls were recruited through the Huntington's 
Disease Multidisciplinary Clinic at the National Hospital for 
Neurology & Neurosurgery in London, United Kingdom, 
from July 2016 to April 2017. All volunteers had to be 18 year 
of age or older, and to have no known contraindication to MRI 
or venepuncture. Early manifest Huntington's disease partic-
ipants were defined as gene expansion carriers (i.e. 40 or 
more CAG repeats in the longer HTT allele) with unequivocal 
signs of Huntington's disease (Unified Huntington's Disease 
Rating Scale [UHDRS] Diagnostic Confidence Level of 4) 
and a good functional status implying early stage disease 
(UHDRS Total Functional Capacity [TFC] between 13 and 
7). Healthy controls were free from significant comorbidities, 
and those with a family history of Huntington's disease, had 
all had a negative test for the Huntington's disease mutation. 
They were age and gender matched to the Huntington's dis-
ease participants.
Exclusion criteria were as follows: inability to tolerate any 
of the procedures involved, chiefly MRI scanning or phlebot-
omy; any clinically significant and relevant history that could 
affect the conduct of the study and evaluation of the data, as 
ascertained by the investigators, or through detailed medical 
history and screening assessments; inability or unwillingness 
to participate in an Enroll- HD core assessment, or for data 
obtained from Enroll- HD to be accessed.
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The study was compliant with the principles of the 
Declaration of Helsinki, and applicable components of 
the International Conference on Harmonisation (ICH) 
Good Clinical Practice (GCP). It was approved by the 
 London-Queen  Square ethics committee, and all participants 
gave written informed consent.
2.2 | Clinical and laboratory assessments
All participants, excluding the optimization controls, were 
subject to a detailed clinical evaluation before undergoing 
the MRI scan, including the Enroll- HD core assessment, 
which includes the UHDRS- 99 (Huntington Study Group, 
1996; Siesling, van Vugt, Zwinderman, Kieburtz, & Roos, 
1998). Overall, the core assessment contains: demographic 
data; height and weight; alcohol, tobacco and drug history; 
family history; characteristics of the disease; genetic test-
ing history; past medical history; comorbid conditions; 
pharmacotherapy, non- pharmacological therapy, nutri-
tional supplements; the UHDRS TMS; the UHDRS TFC; 
the UHDRS Functional Assessment (FA); the UHDRS 
Independence Scale (IS); the Symbol Digit Modality Test 
(SDMT); the Categorical Verbal Fluency Test (CVFT); 
the Stroop Color Naming Test; the Stroop Word Reading 
Test; and the Problem Behaviors Assessment Short (PBA- 
s; Craufurd, Thompson, & Snowden, 2001). The disease 
burden score (DBS) – age × (CAG- 35.5) – was calculated 
for all people with early manifest Huntington's disease 
(Paulsen et al., 2006, 2008).
A blood sample (approx. 10 ml) was collected in EDTA 
tubes (BD, NJ, USA) for osmolality measurement. Analytes’ 
concentrations were quantified by freezing point depression, 
and osmolality was computed according to the following 
formula:
2× (Na+K)+urea+glucose.
F I G U R E  1  Cerebrospinal fluid 
dynamics PCMRI analysis pipeline. (a) 
Representative example of localisation of 
the cerebral aqueduct on midline sagittal 
T1- weighted image; (b) first and (c) 
eighth thoracic vertebral body localisation 
on midline sagittal T2- weighted image. 
PCMRI analysis was performed on slices 
perpendicular to the expected direction of 
flow at the level of interest, selected by 
an experienced radiographer (yellow lines 
in a, b and c). (d) Representative axial 
T2- weighted MRI at the level of the lamina 
quadrigemina, showing clearly visualised 
and delineated cerebral aqueduct (yellow 
circle). Representative cardiac- gated PCMRI 
image at the same level (low intensity 
representing negative flow velocities (e) 
and high intensity positive flow (f) at a 
later phase of the cardiac cycle) together 
with the manual demarcation of the area 
of interest (red). (g) Shows an example of 
a typical normal sinusoidal graph mean 
of CSF velocity (cm/s) over time (ms) 
for each phase of the cardiac cycle, in the 
cerebral aqueduct; data such as these were 
used to generate the flow and velocity 
measurements investigated in the study
1 mm 1 mm
(a)
(d) (e)
(g)
(f)
(b) (c)
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2.3 | Structural brain imaging
T1 and T2- weighted MRI data were acquired on a 3T scan-
ner, using a protocol designed for this study (Supporting 
Information: Imaging Methods). From T1- weighted scans we 
segmented whole- brain, ventricles, and total intracranial vol-
ume (TIV) with Medical Image Display Analysis Software 
(MIDAS); and volumes of grey and white matter, and intrac-
ranial CSF volumes with Statistical Parametric Mapping 12 
(SPM12). T2- weighted scans were stitched and total CSF 
volumes were calculated using MIDAS, using a protocol that 
was validated internally. All segmentations underwent visual 
quality control to ensure accurate delineation of the regions. 
No scans failed processing. Brain and ventricle volumes are 
expressed as a percentage of total intracranial volume, to ac-
count for overall head size.
2.4 | CSF flow and velocities quantification
PCMRI was used to quantify CSF velocity and flow at three 
levels of interest (LOI): the cerebral aqueduct, and the spi-
nal subarachnoid space at the level of the first (T1), and 
eighth (T8) thoracic vertebral bodies (Figure 1a,b, and c, 
respectively). Peripheral cardiac gating was performed via 
an MRI-compatible pulse oximeter. Oblique- axial slices 
for PCMRI were prescribed based on T1- weighted brain 
images and T2- weighted spine images, both perpendicu-
lar to the expected direction of flow as assessed by an ex-
perienced radiographer. Flow velocity encoding was then 
performed in the through- slice direction (perpendicular to 
the expected direction of flow). The maximum encoding 
velocity was 20 cm/s. For the cerebral aqueduct, 32 cardiac 
phases were recorded, with repetition time (TR) = 31 ms, 
echo time (TE) = 10 ms, field of view 135 × 135 mm 
(100% phase oversampling), in- plane spatial resolution 
0.53 mm × 0.70 mm and 5 mm slice thickness (acquisi-
tion time approx. 6.5 min). For T1 level, 25 cardiac phases 
were recorded with TR = 31 ms, TE = 10 ms, field of view 
135 mm × 135 mm (100% phase oversampling), in- plane 
spatial resolution 0.53 mm × 0.70 mm and 5 mm slice thick-
ness (acquisition time approx. 6.5 min). For T8 level, same 
number of cardiac phases, TE, TR, and slice thickness as 
for T1, field of view 150 mm × 150 mm (100% phase over-
sampling), in- plane spatial resolution 0.59 mm × 0.65 mm 
(acquisition time approx. 7.6 min). Flow scans underwent 
quality control at the time of acquisition and prior to pro-
cessing. This protocol was optimized using the scans of 10 
healthy volunteers.
A single set of T8 level PCMRI images from a male man-
ifest HD participant was excluded due to the presence of mo-
tion artifact.
Two independent investigators (FBR and RIS), blinded 
to participant's disease status, analysed all datasets in 
duplicate. The investigators were instructed to draw man-
ually one region of interest (ROI) per LOI per participant, 
only selecting pixels with flow during the cardiac cycle, 
while maximizing the number of pixels included in the 
analyses. For each ROI, CSF velocity and flow for each 
cardiac phase were calculated using a built in commercial 
flow analysis package (Argus Flow, Siemens Healthcare, 
Erlangen, Germany) as shown in Figure 1; our analyses 
then used the averages over the complete cardiac cycle. 
Flow values were calculated in millilitres per minute; 
mean velocity and peak velocity were calculated in centi-
metres per second.
2.5 | Statistical analysis
Statistical analyses were performed using Stata v14.2 
(College Station, TX). All analysis were carried out blind to 
subject group. The threshold for statistical significance for all 
analyses was p < 0.05.
Inter- group differences in demographic variables were 
tested using two- sample Wilcoxon rank- sum (Mann–
Whitney) test for continuous variables, or Fisher's exact test 
for categorical variables.
To quantify the agreement between measurements, 
individual interclass correlations (ICCs) for flow and ve-
locity measurements were calculated between the two rat-
ers (FBR and RIS) using a two- way mixed effect model. 
Only measures with an ICC over 0.75 were included in the 
analysis.
For all the analyses below, the velocity and flow values 
used were a mean of the values generated independently by 
each investigator.
Non- parametric Spearman's rank correlation analyses 
were done to test the effect of age and serum osmolality on 
CSF flow and velocities in healthy controls, and CAG and 
DBS in gene expansion carriers. The same was done for brain 
volumes in healthy controls.
Inter- group comparisons of CSF flow parameters were 
performed using a two- sample Wilcoxon rank- sum (Mann–
Whitney) tests, and as a sensitivity analysis, a t test for equal 
(Student's) or unequal (Welch's) variances according to the 
variable.
Additional models were constructed to examine the re-
lationship among velocity and flow parameters and clinical 
data, CAG, DBS, serum osmolality and brain volumes if 
there was a statistically significant effect on these covariates 
on the study variables.
Finally, we used the largest magnitude of effect and the 
most clinically significant variable, as calculated according 
to the Hedges’ g, to produce sample size computations for fu-
ture comparisons of two independent means, using an alpha 
(type I error) of 0.05, and a beta (type II error) of 0.20 and 
0.10.
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2.6 | Data availability
Access to the full dataset used in this work will be granted 
upon request to the lead author.
3 |  RESULTS
Twenty participants were recruited, 10 for each group 
(Table 1). Groups were well balanced in regards to gender, 
age, ethnicity, and serum osmolality. CSF flow during the 
cardiac cycle showed a sinusoidal time dependence with 
cranio- caudal flow coincident with the first- phase of the car-
diac cycle, followed by caudo- cranial flow (Figure 1g).
Five out of the nine studied measures attained good- to- 
excellent agreement between raters (Supporting Information 
Table S1) and were further included in the analyses; all others 
were excluded.
In the healthy controls, we studied the effect of age, gen-
der, serum osmolality, and brain volumes. None of these 
variables was significantly associated with the study mea-
surements at any level of interest, before or after adjust-
ment for multiple comparisons (Supporting Information 
Table S2).
Velocities and flow at each level of interest are shown 
in Table 1. No significant differences were found between 
groups for any measure at any level (Figure 2). We then 
explored whether CSF flow characteristics were related to 
factors that influence Huntington's disease severity, namely 
the length of the pathogenic CAG expansion in the HTT 
gene, and its interaction with age. None affected the study 
measurement consistently at any level of interest, before 
All Healthy controls Manifest HD p- Value
N (%) 20 10 (50%) 10 (50%) n/a
Males, n (%) 10 (50%) 5 (50%) 5 (50%) 1.0000a
Age, years, median 
(IQR)
57 (18.5) 51.5 (13) 60 (8) 0.1120
Caucasian, n (%) 20 (100%) 10 (100%) 10 (100%) 1.0000a
CAG, median (IQR) n/a n/a 42 (3) n/a
TFC, median (IQR) 13 (2) 13 (0) 11 (2) 0.0002
FA, median (IQR) 25 (2) 25 (0) 23 (3) 0.0002
IS, median (IQR) 100 (20) 100 (0) 80 (15) 0.0002
TMS, median (IQR) 8.5 (22.5) 1.5 (2) 24 (32) 0.0001
SDMT, median (IQR) 40.5 (16) 47.5 (13) 34 (18) 0.0025
CVFT, median (IQR) 23 (7) 24.5 (6) 18.5 (12) 0.0254
SCNT, median (IQR) 65.5 (22.5) 71.5 (11) 50 (14) 0.0022
SWRT, median (IQR) 91 (28.5) 97.5 (19) 69.5 (37) 0.0051
Osmolality, mosmol/
kg, median (IQR)
293 (7) 293 (4) 293 (5) 0.4585
CA peak velocity, 
cm/s, median (IQR)
9.17 (5.40) 7.42 (3.91) 10.72 (4.08) 0.112
CA mean velocity, 
cm/s, median (IQR)
0.14 (0.18) 0.11 (0.26) 0.15 (0.08) 0.385
CA mean flow, ml/
min, median (IQR)
0.29 (0.32) 0.21 (0.36) 0.29 (0.21) 0.570
T1 peak velocity, 
cm/s, median (IQR)
4.93 (2.28) 5.66 (2.76) 4.93 (1.46) 0.326
T8 peak velocity, 
cm/s, median (IQR)
5.18 (3.51) 4.99 (2.05) 6.22 (3.28) 0.624
Notes. %: percentage of participants; CA: cerebral aqueduct; CAG: CAG repeat length; CVFT: Categorical 
Verbal Fluency Test; FA: Unified Huntington's Disease Rating Scale Functional Assessment; IQR: interquartile 
range; IS: Unified Huntington's Disease Rating Scale Independence Scale; n: number of participants; n/a: not 
applicable; SCNT: Stroop Color Naming Test; SDMT: Symbol Digit Modality Test; SWRT: Stroop Word 
Reading Test; T1: spinal subarachnoid space at the level of the first thoracic vertebral body; T8: spinal subarach-
noid space at the level of the eighth thoracic vertebral body; TFC: Unified Huntington's Disease Rating Scale 
Total Functional Capacity; TMS: Unified Huntington's Disease Rating Scale Total Motor Score.
aFisher's exact test, otherwise two- sample Wilcoxon rank- sum (Mann–Whitney) test. 
T A B L E  1  Participants’ characteristics, 
and velocity and flow measurements per 
study group. Peak and mean velocities are 
shown in cm/s, and mean flows in ml/min
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or after adjustment for multiple comparisons (Supporting 
Information Table S3).
Finally, we calculated sample sizes for the measure with 
the largest effect size (peak velocity at the cerebral aqueduct), 
and of the most clinically meaningful measure for intrathecal 
bolus injections (peak velocity in the lower spine). Thirty- 
seven participants per group would be needed to show a signif-
icant difference between two groups with 90% power for the 
largest effect size and 701 for the most clinically meaningful.
4 |  DISCUSSION
Our results suggest that no clinically significant disease- 
related differences in CSF dynamics exist between people 
with early stage Huntington's disease and healthy controls, 
at the level of the cerebral aqueduct, upper spine and lower 
spine. Because this was a small, single- centre study, our re-
sults require external validation, but the attained effect sizes 
suggest that if such differences do exist, they are likely to be 
so small that they need not be factored in when designing 
intrathecal trials in Huntington's disease.
PCMRI has some technical limitations. The strategy 
used to define the ROIs may limit comparability between 
studies, and the inherent limit of spatial resolution may 
introduce error due to partial volume effects. While the 
adoption of semi- automated segmentation techniques may 
improve measurement consistency, to minimise variation 
we developed a manual delineation protocol to identify re-
gions of interest. This was applied independently by two 
investigators, blinded to disease group, allowing us to ex-
clude those measures that had a sub- threshold level of in-
terrater concordance, and the degree of variability in the 
measures selected for our analysis is in agreement with pre-
vious reports.
At the level of the cerebral aqueduct, all three mea-
sures had excellent agreement between investigators. The 
aqueduct is tubular, which favours laminar flow, and has 
well- defined margins. In contrast the agreement between 
investigators was lower in the spinal subarachnoid space. 
CSF here flows around the spinal cord and is naturally more 
complex.
Peak velocity was more consistent between measure-
ments based on ROIs defined by different operators, probably 
F I G U R E  2  Cerebrospinal fluid flow and velocities do not seem to be different between healthy controls (grey plots) and people with early 
Huntington's disease (red plots). Faded plots were variables with a sub- threshold agreement between raters, which were not formally analysed. The 
boxes extend from the 25th to the 75th percentile with a vertical line for the median (50% percentile). The whiskers extend to the lower and the upper 
adjacent values (1.5 times the interquartile range plus the 25th or the 75th percentile, respectively). All values outside this range were considered outliers
0 3 6 9 12 15 0 3 6 9 12 15 0 3 6 9 12 15
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
0 3 96 1512 0 3 6 9 12 15 0 3 96 1512
Cerebral aqueduct Spinal subarachnoid space at the first thoracic vertebral body
Spinal subarachnoid space at 
the eight thoracic vertebral body
Peak velocity
(cm/s)
Mean velocity
(cm/s)
Mean flow
(mL/min)
p-value = 0.112 p-value = 0.326
p-value = 0.385
p-value = 0.570
p-value = 0.624
Healthy controls Early Huntington’s disease
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because it represents the maximum velocity within the ROI, 
and thus is essentially independent of the manual anatomical 
ROI delineation. Mean velocities and flows could be clini-
cally more informative than peak velocities, as they inform 
on the volume and speed of CSF flow across a region of the 
sub- arachnoid space, and not only on an extreme value as 
the peak velocity does. Unfortunately they are more difficult 
to determine accurately and precisely, as they depend on the 
anatomical delineation of the ROI. Our values for flow at the 
cerebral aqueduct are broadly concordant with previous stud-
ies (Huang et al., 2004; Luetmer et al., 2002; Yoshida et al., 
2009) and supported by the classic physiological concept that 
CSF is produced at a rate of 0.3–0.4 ml/min (Brinker et al., 
2014).
Overall, our results do not suggest that CSF dynamics 
are meaningfully altered in early stage Huntington's dis-
ease. External validation across disease stages and utilizing 
a larger sample is needed, but the apparent effect sizes are 
in keeping with effects that are either absent or of minimal 
clinical relevance. This is reassuring as targeted molecular 
therapeutics delivered by bolus intrathecal injection enter 
large- scale clinical trials.
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